ReviewAIDS research and therapy2016
What happens to cardiovascular system behind the undetectable level of HIV viremia?
Review in AIDS research and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Impact of low-level viremia on HIV non-viral load suppression in low and middle-income countries.Annals of medicine and surgery (2012) · 2025Review
- A Disintegrin and Metalloprotease with Thrombospondin Motif, Member 13, and Von Willebrand Factor in Relation to the Duality of Preeclampsia and HIV Infection.International journal of molecular sciences · 2025Review
- Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study.AIDS research and treatment · 2025Article
- Review
- Review
- Patient Experience Evaluation of the CMO-Based Pharmaceutical Care Model vs Usual Care in People Living with HIV.Journal of multidisciplinary healthcare · 2022Article
- Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status.Virulence · 2021Review
- Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population.Journal of personalized medicine · 2021Article
- Silver Nanoparticles Conjugate Attenuates Highly Active Antiretroviral Therapy-Induced Hippocampal Nissl Substance and Cognitive Deficits in Diabetic Rats.Journal of diabetes research · 2021Article
- Pyrimidine 2,4-Diones in the Design of New HIV RT Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- Targeting the HIV-infected brain to improve ischemic stroke outcome.Nature communications · 2019Article
- Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project.Infection and drug resistance · 2019Article
- Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.International journal of medical sciences · 2019Article
- Modelling interaction between HIV-1 Nef and calnexin.AIDS (London, England) · 2018Article
- Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.JCI insight · 2018Article
- Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection.Current cardiology reviews · 2018Review
- Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.JCI insight · 2017Article
- Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART.AIDS research and therapy · 2017Article
- Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns.BMC infectious diseases · 2017Article
- Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFrontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the combined antiretroviral therapy has improved the length and quality of life of HIV infected patients, the survival of these patients is always decreased compared with the general population. This is the consequence of non-infectious illnesses including cardio vascular diseases. In fact large studies have indicated an increased risk of coronary atherosclerotic disease, myocardial infarction even in HIV patients on cART. In HIV infected patients several factors may contribute to the pathogenesis of cardiovascular problems: life-style, metabolic parameters, genetic predisposition, viral factors, immune activation, chronic inflammation and side effects of antiretroviral therapy. The same factors may also contribute to complicate the clinical management of these patients. Therefore, treatment of these non-infectious illnesses in HIV infected population is an emerging challenge for physicians. The purpose of this review is to focus on the new insights in non AIDS-related cardiovascular diseases in patients with suppressed HIV viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.